Joel M Reid, PhD

  • 7294 Citations
  • 44 Scopus h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Joel M Reid is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Medicine & Life Sciences

Pharmacokinetics
irinotecan
Neoplasms
temozolomide
Maximum Tolerated Dose
gemcitabine
Topotecan
Appointments and Schedules
tanespimycin
Carboplatin
Pediatrics
alvocidib
Glioma
NSC 366140
Neutropenia
Therapeutics
Area Under Curve
Leukemia
Neuroblastoma
Half-Life
Pemetrexed
Pharmaceutical Preparations
Pharmacology
Idarubicin
5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Cisplatin
oxaliplatin
antineoplaston AS 2-1
Tamoxifen
Drug Therapy
Nausea
Biological Availability
batracylin
docetaxel
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione)
Cytochrome P-450 Enzyme System
Heterografts
Glioblastoma
Diarrhea
Dacarbazine
Fatigue
Breast Neoplasms
Clinical Trials
Etoposide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
tipifarnib
Thrombocytopenia
Serum
Capsules
Paclitaxel

Chemical Compounds

Pharmacokinetics
gemcitabine
Tumors
Plasmas
irinotecan
Metabolites
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione)
Assays
Rats
Pemetrexed
5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Toxicity